Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions

Young Kwang Chae, Michael S. Oh

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Advances in DNA sequencing methods have significantly expanded the potential clinical applications of analyzing circulating tumor DNA (ctDNA). This genetic information can identify the presence of targetable mutations and has been explored for cancer screening purposes. ctDNA can be obtained without the risks inherent to biopsy, allowing for serial assessments over time. Several studies have additionally suggested that ctDNA can be used to detect the presence of minimal residual disease (MRD) after surgical resection in several cancer types, including lung cancer. The ability to detect MRD would allow clinicians to tailor adjuvant therapies, which carry risks of significant toxicities and may benefit only select groups of patients. Here, we review the current state of ctDNA profiling methods and evaluate the evidence supporting the use of ctDNA analysis to assess for MRD. We discuss how MRD detection could help identify patients at increased risk of disease recurrence and thus guide treatment decisions for resectable lung cancer. Finally, we propose future steps to validate such approaches and expand the utility of these rapidly progressing technologies.

Original languageEnglish (US)
Pages (from-to)16-24
Number of pages9
JournalJournal of Thoracic Oncology
Volume14
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Residual Neoplasm
Lung Neoplasms
DNA
Neoplasms
DNA Fingerprinting
DNA Sequence Analysis
Early Detection of Cancer
Direction compound
Technology
Biopsy
Recurrence
Mutation
Therapeutics

Keywords

  • Liquid biopsy
  • Lung cancer
  • Residual disease
  • ctDNA

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

@article{4276b840a2e741ec9e3b136f368e1b5a,
title = "Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions",
abstract = "Advances in DNA sequencing methods have significantly expanded the potential clinical applications of analyzing circulating tumor DNA (ctDNA). This genetic information can identify the presence of targetable mutations and has been explored for cancer screening purposes. ctDNA can be obtained without the risks inherent to biopsy, allowing for serial assessments over time. Several studies have additionally suggested that ctDNA can be used to detect the presence of minimal residual disease (MRD) after surgical resection in several cancer types, including lung cancer. The ability to detect MRD would allow clinicians to tailor adjuvant therapies, which carry risks of significant toxicities and may benefit only select groups of patients. Here, we review the current state of ctDNA profiling methods and evaluate the evidence supporting the use of ctDNA analysis to assess for MRD. We discuss how MRD detection could help identify patients at increased risk of disease recurrence and thus guide treatment decisions for resectable lung cancer. Finally, we propose future steps to validate such approaches and expand the utility of these rapidly progressing technologies.",
keywords = "Liquid biopsy, Lung cancer, Residual disease, ctDNA",
author = "Chae, {Young Kwang} and Oh, {Michael S.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.jtho.2018.09.022",
language = "English (US)",
volume = "14",
pages = "16--24",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "1",

}

Detection of Minimal Residual Disease Using ctDNA in Lung Cancer : Current Evidence and Future Directions. / Chae, Young Kwang; Oh, Michael S.

In: Journal of Thoracic Oncology, Vol. 14, No. 1, 01.01.2019, p. 16-24.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Detection of Minimal Residual Disease Using ctDNA in Lung Cancer

T2 - Current Evidence and Future Directions

AU - Chae, Young Kwang

AU - Oh, Michael S.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Advances in DNA sequencing methods have significantly expanded the potential clinical applications of analyzing circulating tumor DNA (ctDNA). This genetic information can identify the presence of targetable mutations and has been explored for cancer screening purposes. ctDNA can be obtained without the risks inherent to biopsy, allowing for serial assessments over time. Several studies have additionally suggested that ctDNA can be used to detect the presence of minimal residual disease (MRD) after surgical resection in several cancer types, including lung cancer. The ability to detect MRD would allow clinicians to tailor adjuvant therapies, which carry risks of significant toxicities and may benefit only select groups of patients. Here, we review the current state of ctDNA profiling methods and evaluate the evidence supporting the use of ctDNA analysis to assess for MRD. We discuss how MRD detection could help identify patients at increased risk of disease recurrence and thus guide treatment decisions for resectable lung cancer. Finally, we propose future steps to validate such approaches and expand the utility of these rapidly progressing technologies.

AB - Advances in DNA sequencing methods have significantly expanded the potential clinical applications of analyzing circulating tumor DNA (ctDNA). This genetic information can identify the presence of targetable mutations and has been explored for cancer screening purposes. ctDNA can be obtained without the risks inherent to biopsy, allowing for serial assessments over time. Several studies have additionally suggested that ctDNA can be used to detect the presence of minimal residual disease (MRD) after surgical resection in several cancer types, including lung cancer. The ability to detect MRD would allow clinicians to tailor adjuvant therapies, which carry risks of significant toxicities and may benefit only select groups of patients. Here, we review the current state of ctDNA profiling methods and evaluate the evidence supporting the use of ctDNA analysis to assess for MRD. We discuss how MRD detection could help identify patients at increased risk of disease recurrence and thus guide treatment decisions for resectable lung cancer. Finally, we propose future steps to validate such approaches and expand the utility of these rapidly progressing technologies.

KW - Liquid biopsy

KW - Lung cancer

KW - Residual disease

KW - ctDNA

UR - http://www.scopus.com/inward/record.url?scp=85057224919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057224919&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2018.09.022

DO - 10.1016/j.jtho.2018.09.022

M3 - Review article

VL - 14

SP - 16

EP - 24

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 1

ER -